Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Langer

Showing results (21-30 of 686) with videos related to

Pageof 69
Sort By:
Current Oncology Reports|December 21, 2000
The role of new agents in advanced non-small-cell lung carcinomaC J Langer
Cancer Treatment and Research|February 28, 2001
Staging and prognosis in lung cancer: making the complex accessibleC J Langer
Clinical Lung Cancer|June 28, 2011
Clinical evidence on the undertreatment of older and poor performance patients who have advanced non-small-cell lung cancer: is there a role for targeted therapy in these cohorts?Corey J Langer
Critical Reviews in Oncology/Hematology|January 28, 2012
Individualized therapy for patients with non-small cell lung cancer: emerging trends and challengesCorey J Langer
P & T : a Peer-Reviewed Journal for Formulary Management|July 26, 2011
Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung CancerCorey J Langer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2007
Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancerCorey J Langer
Clinical Advances in Hematology & Oncology : H&O|December 29, 2012
Highlights in NSCLC from the 2012 Chicago Multidisciplinary Symposium in Thoracic OncologyCorey J Langer
Oncology (Williston Park, N.Y.)|February 28, 2001
Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecanC J Langer
The Oncologist|July 22, 2004
Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax)Corey J Langer
Drugs & Aging|March 12, 2008
Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?Corey J Langer
Pageof 69

Showing results (21-30 of 686) with videos related to

Sort By:
Pageof 69
Current Oncology Reports|December 21, 2000
The role of new agents in advanced non-small-cell lung carcinomaC J Langer
Cancer Treatment and Research|February 28, 2001
Staging and prognosis in lung cancer: making the complex accessibleC J Langer
Clinical Lung Cancer|June 28, 2011
Clinical evidence on the undertreatment of older and poor performance patients who have advanced non-small-cell lung cancer: is there a role for targeted therapy in these cohorts?Corey J Langer
Critical Reviews in Oncology/Hematology|January 28, 2012
Individualized therapy for patients with non-small cell lung cancer: emerging trends and challengesCorey J Langer
P & T : a Peer-Reviewed Journal for Formulary Management|July 26, 2011
Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung CancerCorey J Langer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2007
Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancerCorey J Langer
Clinical Advances in Hematology & Oncology : H&O|December 29, 2012
Highlights in NSCLC from the 2012 Chicago Multidisciplinary Symposium in Thoracic OncologyCorey J Langer
Oncology (Williston Park, N.Y.)|February 28, 2001
Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecanC J Langer
The Oncologist|July 22, 2004
Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax)Corey J Langer
Drugs & Aging|March 12, 2008
Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?Corey J Langer
Pageof 69